Comparative Efficacy and Safety of Oral P2Y12 Inhibitors in Acute Coronary Syndrome: Network Meta-Analysis of 52,816 Patients from 12 Randomized Trials.

Conclusions:Prasugrel and ticagrelor reduced ischemic events and increased bleeding in comparison to clopidogrel. A significant mortality reduction was observed with ticagrelor only. There was no efficacy and safety difference between prasugrel and ticagrelor. PROSPERO ID: CRD42019155648.
PMID: 32468837 [PubMed - as supplied by publisher]

Source: Circulation - May 28, 2020 Category: Cardiology Authors: Navarese EP, Khan SU, Kołodziejczak M, Kubica J, Buccheri S, Cannon CP, Gurbel PA, De Servi S, Budaj A, Bartorelli A, Trabattoni D, Ohman EM, Wallentin L, Roe MT, James S Tags: Circulation Source Type: research